Literature DB >> 35357586

Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.

Chenmeng Li1,2, Bei Pan1,2, Xuhong Wang1,2, Xiangxiang Liu1,2, Jian Qin1,2, Tianyi Gao2,3, Huiling Sun2,3, Yuqin Pan4,5, Shukui Wang6,7,8.   

Abstract

PURPOSE: Long intergenic non-coding RNA LINC01088 is a newly discovered long non-coding RNA (lncRNA). Its biological function in colorectal cancer (CRC) remains unknown.
METHODS: Here, 36 paired CRC and para-cancerous tissues were collected. In vitro, fluorescence in situ hybridization (FISH) assay, qPCR, western blotting analysis and cellular functional experiments, RNA immunoprecipitation (RIP) assay and dual-luciferase reporter system analysis were performed. In vivo, xenograft tumor mouse models were generated. Besides, patient-derived intestinal organoid (PDO) was generated ex vivo.
RESULTS: We found that LINC01088 was significantly upregulated in colorectal cancer tissues and CRC cell lines compared to adjacent normal tissues and colonic epithelial cells. High LINC01088 levels were correlated with adverse outcomes in patients with CRC. LINC01088 was mainly located in the cytoplasm. LINC01088 knockdown suppressed the proliferation, migration, invasion, and immune escape of colorectal cancer cells. Mechanistically, LINC01088 bound directly to miR-548b-5p and miR-548c-5p that were significantly upregulated Ras GTPase-activating protein-binding proteins 1 (G3BP1) and programmed death ligand 1 (PD-L1) expression, altering CRC cell phenotypes. In mouse xenograft models, LINC01088 knockdown restrained CRC tumor growth and lung metastasis. Furthermore, G3BP1 overexpression reversed LINC01088-knockdown-mediated inhibitory effects on tumor growth. Notably, LINC01088 knockdown downregulated PD-L1 expression, while G3BP1 overexpression restored PD-L1 expression in xenograft tumors. Besides, LINC01088 knockdown repressed CRC organoid growth ex vivo.
CONCLUSION: Overall, these findings suggested that LINC01088 directly targeted miR-548b-5p and miR-548c-5p, promoting G3BP1 and PD-L1 expression, which facilitated colorectal cancer progression and immune escape.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Colorectal cancer; Immune escape; LINC01088; PD-L1; microRNAs

Mesh:

Substances:

Year:  2022        PMID: 35357586     DOI: 10.1007/s00432-022-03981-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  35 in total

1.  Treatment of Colorectal Cancer: a Multidisciplinary Approach.

Authors:  G Anania; G Resta; S Marino; N Fabbri; L Scagliarini; I Marchitelli; F Fiorica; G Cavallesco
Journal:  J Gastrointest Cancer       Date:  2019-09

Review 2.  LINC00473: A novel oncogenic long noncoding RNA in human cancers.

Authors:  Lingfeng Li; Xu Zhang; Nian Liu; Xiang Chen; Cong Peng
Journal:  J Cell Physiol       Date:  2020-11-22       Impact factor: 6.384

3.  STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses.

Authors:  Amirhossein Jahangiri; Maryam Dadmanesh; Khodayar Ghorban
Journal:  J Cell Physiol       Date:  2020-05-13       Impact factor: 6.384

Review 4.  Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Authors:  Aaron J Franke; William Paul Skelton; Jason S Starr; Hiral Parekh; James J Lee; Michael J Overman; Carmen Allegra; Thomas J George
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

5.  The down-regulation of long non-coding RNA LINC01088 is associated with the poor prognosis of epithelial ovarian cancer patients.

Authors:  H Ai; W Xie; A-H Xiu; N Li; S-T Zhang; Y-L Zhang; X-O Xue
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-09       Impact factor: 3.507

Review 6.  The hallmarks of cancer: a long non-coding RNA point of view.

Authors:  Tony Gutschner; Sven Diederichs
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

7.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

Review 8.  Regulation of PD-L1 Expression by NF-κB in Cancer.

Authors:  Fabrizio Antonangeli; Ambra Natalini; Marina Chiara Garassino; Antonio Sica; Angela Santoni; Francesca Di Rosa
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

9.  Long intergenic non-coding RNA LINC00485 exerts tumor-suppressive activity by regulating miR-581/EDEM1 axis in colorectal cancer.

Authors:  Chenmeng Li; Bei Pan; Xiangxiang Liu; Jian Qin; Xuhong Wang; Bangshun He; Yuqin Pan; Huiling Sun; Tao Xu; Xueni Xu; Kaixuan Zeng; Shukui Wang
Journal:  Aging (Albany NY)       Date:  2021-01-10       Impact factor: 5.682

10.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.

Authors:  Bo Li; Eric Severson; Jean-Christophe Pignon; Haoquan Zhao; Taiwen Li; Jesse Novak; Peng Jiang; Hui Shen; Jon C Aster; Scott Rodig; Sabina Signoretti; Jun S Liu; X Shirley Liu
Journal:  Genome Biol       Date:  2016-08-22       Impact factor: 13.583

View more
  1 in total

1.  Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis.

Authors:  Xu-Sheng Liu; Chao Liu; Jing Zeng; Dao-Bing Zeng; Yi-Jia Chen; Fan Tan; Yan Gao; Xiao-Yu Liu; Yu Zhang; Yao-Hua Zhang; Zhi-Jun Pei
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.